CSL Limited (ASX: CSL)
Australia
· Delayed Price · Currency is AUD | Market Cap | 133.28B |
| Revenue (ttm) | 32.11B |
| Net Income (ttm) | 5.77B |
| Shares Out | 482.83M |
| EPS (ttm) | 11.89 |
| PE Ratio | 35.31 |
| Forward PE | 31.35 |
| Dividend | 3.81 (1.38%) |
| Ex-Dividend Date | Mar 11, 2024 |
| Volume | 420,021 |
| Open | 276.00 |
| Previous Close | 275.39 |
| Day's Range | 274.44 - 277.50 |
| 52-Week Range | 228.65 - 312.99 |
| Beta | 0.29 |
| Analysts | n/a |
| Price Target | 301.32 (+9.25%) |
| Earnings Date | Feb 13, 2024 |
About CSL Limited
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency an... [Read more]
Financial Performance
In 2023, CSL Limited's revenue was $19.59 billion, an increase of 35.36% compared to the previous year's $14.47 billion. Earnings were $3.34 billion, an increase of 7.30%.
Financial numbers in USD Financial StatementsNews
Recently Published Real-World Evidence Study Shows Effectiveness of Cell-Based Quadrivalent Influenza Vaccine Over Three Seasons
A real-world evidence (RWE) study recently published in Open Forum Infectious Diseases (OFID) examined three consecutive U.S. flu seasons in the United States. The study suggests that cell-based quadr...
CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
First non-immunosuppressive therapy for the treatment of IgA Nephropathy (IgAN) approved in Europe Conditional marketing authorization is based on statistically significant and clinically meaningful r...
Ferinject® approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure
ST. GALLEN, SWITZERLAND , March 19, 2024 /PRNewswire/ -- CSL Vifor today announced that Health Canada has authorized Ferinject (ferric carboxymaltose) for the intravenous (IV) treatment of iron defici...
CSL Seqirus is Fully Prepared to Implement the FDA's Vaccines and Related Biological Products Advisory Committee Trivalent Influenza Vaccines Strain Selection for the 2024/25 U.S. Season
SUMMIT, N.J. , March 6, 2024 /PRNewswire/ -- CSL Seqirus, a global leader in the protection of public health, confirmed it is fully prepared to deliver its influenza vaccine portfolio for the 2024/25 ...
20 Biggest Health Care Companies in Australia, 2024
CSL Limited led the Health Care Companies listed on the Australian Securities Exchange as of March 2024, with a market capitalization of over 135.02 billion Australian dollars. Meanwhile, Cochlear Lim...
CSL Vifor and Travere Therapeutics announce sparsentan receives positive CHMP opinion for the treatment of IgA nephropathy
Committee for Medicinal Products for Human Use (CHMP) recommends approval of the conditional marketing authorization (CMA) for sparsentan for the treatment of IgA nephropathy (IgAN) in Europe Positive...
Australia’s Largest Companies by market capitalization, 2024
As of February 17, 2024, Vanguard US Total Market Shares Index is the most valuable company in Australia, with a market cap of $371 billion. Following it are BHPGroup Limited ($149 billion) and Common...
CSL Limited: Earnings Beat Doesn't Mask Unfavorable Trial Results (Downgrade)
CSL Ltd (CSLLY) Q2 2024 Earnings Call Transcript
CSL Ltd Capital Markets Day Transcript
CSL Ltd Capital Markets Day Transcript
CSL Ltd Market Update Call Transcript
CSL Ltd Market Update Call Transcript
CSL Ltd Ordinary Shareholders Meeting Transcript
CSL Ltd Ordinary Shareholders Meeting Transcript
CSL Ltd Research and Development Investor Briefing Transcript
CSL Ltd Research and Development Investor Briefing Transcript
CSL Ltd Vifor Investor Briefing Transcript
CSL Ltd Vifor Investor Briefing Transcript
CSL Ltd R&D Investor Briefing Transcript
CSL Ltd R&D Investor Briefing Transcript
CSL Ltd Annual Shareholders Meeting Transcript
CSL Ltd Annual Shareholders Meeting Transcript
CSL Ltd Operations Update Call Transcript
CSL Ltd Operations Update Call Transcript
Half year reported NPATA US$2 billion¹,² Up 13% at constant currency³
Strong CSL Behring portfolio growth especially Ig FINANCIAL HIGHLIGHTS 4 Revenue $8.05 billion, up 11% at CC3 NPAT $1.90 billion 1, up 17% NPAT $1.94 billion 1 at CC3, up 20% NPATA $2.02 billion 1,2 ,...
CSL Limited falls after Phase 3 setback for key trial
CSL Announces Top-line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I [human])
KING OF PRUSSIA, Pa. , Feb. 11, 2024 /PRNewswire/ -- Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced top-line results from the Phase 3 AEGIS-II trial evaluating the efficacy and...
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster
Study conducted by Meiji Seika Pharma in Japan Short communication follows previously published data in The Lancet Infectious Diseases demonstrating Immunological Non-Inferiority to Wuhan Strain and ...
Harris Poll Survey Finds People Receiving Treatment for CIDP Are Interested in Exploring More Convenient Treatment Options
Findings show that convenience of treatment and flexibility of administration, such as at-home treatment options, are of high importance to patients KING OF PRUSSIA, Pa. , Jan. 16, 2024 /PRNewswire/ -...
CSL Behring Announces Availability of Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) 10g Prefilled Syringe
- Hizentra® is the #1 immune globulin prescribed for Primary Immunodeficiency (PI) in the U.S.- Hizentra is the first and only subcutaneous immune globulin (SCIg) treatment approved for Chronic ...
CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster
Study conducted by Meiji Seika Pharma in Japan Data follow approval of the world's first self-amplifying messenger RNA (sa-mRNA) COVID-19 vaccine for adults by Japan Ministry of Health, Labor and Welf...